Hadassah

Placental Stem Cell Therapy to Treat Acute Radiation Syndrome Receives Boost from FDA

Tuesday, Oct 24 2017

Prof. Raphael Gorodetsky

In collaboration with Pluristem Therapeutics, the Hadassah Medical Organization developed a stem cell product from the human placenta to prevent and treat acute radiation syndrome (ARS). The product, PLX-R18, has just received orphan drug status from the U.S. Food and Drug Administration (FDA).

“Receiving orphan drug designation brings us one step closer to providing a next-generation medical countermeasure against ARS,” notes Zami Aberman, Co-Chief Executive Officer and Chairman of Pluristem.

As Pluristem explains: The designation involves close guidance by the FDA, which may accelerate the path to potential marketing approval; orphan drug grants; tax credits; and seven-year market exclusivity upon marketing approval.

ARS (sometimes known as radiation toxicity or radiation sickness) is an acute lethal illness caused by irradiation of the entire body (or most of the body) by a high dose of penetrating radiation in a very short period of time. The syndrome affects the body’s ability to form new blood cells (hematopoietic recovery). PLX therapy holds promise as a new treatment for cancer patients who suffer complications following high-dose radiation and chemotherapy.

The earlier, less effective version of PLX cell therapy was tested initially at Hadassah on terminally ill patients who had no other treatment option. The results were “very good,” reports Prof. Raphael Gorodetsky, head of the Biotechnology and Radiobiology Laboratory in Hadassah’s Sharett Institute of Oncology.

Pluristem recently reported positive data from non-human primate studies of PLX-R18 treatment for ARS. Conducted by the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH), the study revealed improvement in survival rates and the enhancement of recovery across all three major blood lineages: white blood cells, red blood cells, and platelets.

Pluristem reports also that PLX-R18 cells are being studied by the U.S. Department of Defense’s Armed Forces Radiobiology Research Institute to examine the effectiveness of the cells as a treatment for ARS prior to, and within the first 24 hours of, exposure to radiation. Pluristem PLX-R18 cells are also being studied by Fukushima Medical University in Japan for the treatment of ARS and as an adjunct to radiotherapy in cancer patients.

A clinical trial at Hadassah with PLX-R18 is now in the planning stages, Prof. Gorodetsky relates. 

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jul 19 2018

Hadassah Doctors in Forefront of Diabetes Prevention and Treatment

“Diabetes is on track to become the largest epidemic in human history.” So says Dr. Gil Leibowitz, incoming head of the Hadasah Diabetes Center at Hadassah Hospital Ein Kerem, and himself a diabetic since the age of seven.

READ MORE ›
alt_text

Wednesday, Jul 11 2018

Improving Kidney Health of Premature Babies

Is the TV hit show Grey's Anatomy taking its inspiration from Hadassah Hospital? After all, cast members did visit Hadassah Ein Kerem in 2011. Dr. Oded Volovelsky, Head of Hadassah's new Pediatric Nephrology Unit says, only half-jokingly, that TV doc Meredith Grey might have read his research.

READ MORE ›
alt_text

Wednesday, Jul 11 2018

Hadassah Cancer Specialists Explore Link Between Colorectal Cancer and BRCA Mutations

Looking further into the link between colorectal cancer and BRCA 1 and 2 genetic mutations, researchers from the Hadassah Medical Center’s Sharett Institute of Oncology, together with colleagues from Chaim Sheba Medical Center, analyzed data from 32 patients with lower gastrointestinal cancers.

READ MORE ›
alt_text

Monday, Jul 9 2018

World Hepatitis Day: Hadassah’s Contribution to the Global Battle Against this Disease

“Hadassah Medical Organization's (HMO) greatest contribution to the global battle against Hepatitis are the vaccines that have been developed here,” said Prof. Daniel Shouval, as we mark World Hepatitis Day on July 28.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More